Use of an ErbB2 inhibitor for promoting ErbB2- regulated autophagic degradation or clearance of APP-C99 and APP intracellular domain （AICD） and/or alleviating production of Aβ40 and Aβ42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an ErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof.本發明公開一種ErbB2抑制劑用於促進ErbB2-調節的自噬降解或清除APP-C99與APP胞內結構域（AICD）及/或在一需要該抑制劑的受試者中減緩Aβ40與Aβ42生成的用途。本發明亦公開一種ErbB2抑制劑用於在一需要該抑制劑的受試者中避免ErbB2-調控的自噬作用之抑制的用途。本發明進一步公開一種ErbB2抑制劑用於在一患有與ErbB2相關的阿茲海默症之受試者中增強空間學習與記憶，及/或用於改善認知的用途。本發明亦公開一種ErbB2抑制劑用於在一需要該抑制劑的受試者中降低C99與AICD的胞內含量，而不影響胞外結構域短縮型Notch及Notch胞內結構域。
